Compare MasterCard Inc (MA) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Repligen Corporation Common Stock — how do they compare? MasterCard Inc trades at $606.06 (market cap $529.81B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: MasterCard Inc is far larger — about 47.6× Repligen Corporation Common Stock's market cap, and MasterCard Inc pays a 0.58% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 135 Days and Repligen Corporation Common Stock for 0 Days on average.
| MA | RGEN | |
|---|---|---|
Market Cap | $529.81B | $11.14B |
Volume | 3,710,695 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $604.80 | $194.57 |
52-Week Low | $471.55 | $102.87 |
Typical Hold Time | 135 Days | 0 Days |
Enterprise Value | $542.84B | $11.02B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $603.24, up 1.37% on the day, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent revenue growth from $22.2B in 2022 to $32.8B in 2025, net income margins above 45%, and three consecutive quarterly earnings beats. Institutional buying activity remains strong, with multiple funds increasing positions in Q4 2025.
Outlook remains positive with 80% analyst buy ratings and $668.67 consensus price target, representing 11% upside. Key risks include payment industry disruption from stablecoins and AI-driven competitors, though Mastercard's aggressive innovation strategy and expanding digital inclusion initiatives provide growth catalysts. The stock trades near resistance at $603 with support at $591.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
